“old” anticoagulants and renal insufficiency

“Old” anticoagulants and renal insufficiency

Pirmin Schmid

Division of Hematology and Central Hematology Laboratory Luzerner Kantonsspital, Luzern, Switzerland

“Old” anticoagulants and renal insufficiency

Pirmin Schmid

Division of Hematology and Central Hematology Laboratory Luzerner Kantonsspital, Luzern, Switzerland

Disclosures •  Former investigator in a pharmacokinetic study on dalteparin in renal

insufficiency, funded by Luzerner Kantonsspital and an unrestricted grant by Pfizer Switzerland

Agenda

•  Introduction •  Vitamin K antagonists (VKA) •  Unfractionated heparins (UFH) •  Low-molecular-weight heparins (LMWH)

– Pharmacokinetics – Clinical data

•  Summary

Renal Insufficiency - Prevalence

95%

4.30%

Population

76%

15%

4% 5%

Inpatients

≥ 60

30-59

15-29

<15

GFR [mL/min]

Levey et al. Ann Int Med 2003:137-47 Schmid et al. Swiss Med Wkly 2007:514

LMWH: Bleeding risk

Lim et al. Ann Intern Med 2006:673

Risks: Bleeding / Thrombosis

•  Balance the increased risks – bleeding –  thromboembolic events

–  increased bleeding risk not dependent on used anticoagulant

– TE events > bleeding

Geerts. Chest 2008:381S-453S / Schulman. Chest 2008:257S-298S / Monreal. Am J Med 2006:1073-9

Vitamin K antagonists (VKA)

US drug monograph

•  since 1950s •  metabolism: hepatic

t½ renal fraction of final excretion

Warfarin ~ 40 h ~ 90%

Warfarin dose in RI

•  moderate RI Δ dose - 9.5 % •  severe RI Δ dose - 19 %

à adjust dose to INR

Limdi et al. Am J Kidney Dis 2010:823-31

Vitamin K antagonists (VKA)

Swiss and US drug monographs

•  since 1950s •  metabolism: hepatic

t½ renal fraction of final excretion

Acenocoumarol ~ 8-11 h ~ 60%

Warfarin ~ 40 h ~ 90%

Phenprocoumon ~ 160 h ~ 35%

“Warfarin related nephropathy”

•  over-anticoagulation (INR > 3.0) à renal function can decrease

•  Cohort study, n=4006, 5 years •  WRN event: SC increased by 0.3 mg/dl

within 1 week after INR > 3.0 •  WRN in 20% (complete population),

in 33% (patients with CKD)

•  1-year mortality with WRN 31% without WRN 19%

Brodsky et al. Kidney International 2011:181-9

VKA: time in range

Meta-analysis 60%

Anticoagulation clinics or family doctor 32 - 77%

self-monitoring target range 72%

self-monitoring safety range 2.0 – 4.5 95%

INR

time

Reynolds. Chest 2004:1938-45 / Heneghan. Lancet 2006:404-11 / Fritschi. Swiss Med Wkly 2007:252-8

VKA and severe RI

•  adjust dose to target INR •  dose may be lower (20%) •  inter-individual variability •  caution: over-anticoagulation

– bleeding risk – kidney damage

à more frequent INR checks à patient education

Unfractionated heparin (UFH) •  discovered 1916, clinical trials 1935 •  sulphated glycosaminoglycan, 12-15 kDa •  bound to plasma proteins •  Metabolism: RES, liver heparinases •  Excretion: renal, mostly inactive, depolymerized

•  t½ 30-120 min à continuously i.v. à frequently s.c. (bioavailability only 15-40%)

Swiss drug monograph

Unfractionated heparin (UFH) •  Liver function / kidney function •  Acute phase

•  Monitoring: anti-Xa activity, aPTT, TT, PiCT

•  Adjust dose to target range

•  Advantages –  short t½ –  antagonist Protamine

LMWH •  depolymerized UFH •  in general more effective and safer than UFH

•  known for renal clearance à accumulation

•  intermittent use for hemodialysis

ACCP 8th / Hirsh et al. Chest 2008:141S-59S

LMWH: Metabolism & Elimination

LMWH *

Urine

Radioactivity 100%

Radioactivity 69%

1. LMWH and Renal Clearance

Palm & Mattsson. Thromb Haemost 1987:932-5 / Collignon. Thromb Haemost 1995:630-40 / Frydman. Haemostasis 1996;Suppl 2:24-38

LMWH: Metabolism & Elimination

LMWH *

Urine

Radioactivity 100% Anti-Xa activity 100%

Radioactivity 69% Anti-Xa activity 10%

1. LMWH and Renal Clearance

Palm & Mattsson. Thromb Haemost 1987:932-5 / Collignon. Thromb Haemost 1995:630-40 / Frydman. Haemostasis 1996;Suppl 2:24-38

LMWH: Metabolism & Elimination

LMWH *

Urine

Radioactivity 100% Anti-Xa activity 100%

Radioactivity 69% Anti-Xa activity 10%

2. Various LMWH

Renal fraction of total drug clearance

Dalteparin 3% Nadroparin 4% Enoxaparin 6-8%

Palm & Mattsson. Thromb Haemost 1987:932-5 / Collignon. Thromb Haemost 1995:630-40 / Frydman. Haemostasis 1996;Suppl 2:24-38

Apparent t½

Schmid et al. Swiss Med Wkly 2009:438-52

Properties of LMWHs LMWH

UFH Tinzaparin Dalteparin Enoxaparin Nadroparin Fondaparinux

MW (kDa)

15 6.5 6 4.5 4.3 1.7

anti-Xa : IIa

1.0

1.5-1.8

2.2-2.5

1.8-2.0

2.5-4.0

>30

Renal fraction of clearance

Accumulation

Frydman. Haemostasis 1996;26(Suppl 2):24-38 Schmid et al. Swiss Med Wkly 2009:438-52

Observation time

Sanderink et al. Thromb Res 2002:225-31

•  Enoxaparin 40 mg / d •  n=12 in each group •  Pharmacokinetic profiles

Observation time

Data from Sanderink et al. Thromb Res 2002:225-31

Observation time

Sanderink et al. Thromb Res 2002:225-31

•  Enoxaparin 40 mg / d •  n=12 in each group •  Pharmacokinetic profiles

Observation time

Data from Sanderink et al. Thromb Res 2002:225-31

t½ vs. τ •  Bioaccumulation related to ratio of t½ and τ

•  LMWH t½ 3-4 h •  Prophylaxis τ 24 h •  Therapeutic τ 12 h (or high dose / 24 h)

•  Consequence: Recommendations for prophylaxis (may) differ from therapy

t½ vs. τ

Model

t½ vs. τ

Model

t½ vs. τ

Model

t½ vs. τ

Model

Apparent t½

Schmid et al. Swiss Med Wkly 2009:438-52

LMWH

•  various LMWH à different properties à different pharmacokinetics

•  Different setting: Prophylaxis – Therapy – Recommendations (may) differ

•  Long-term data needed for proper PK data

•  Clinical end points

Enoxaparin

•  Most data: pharmacokinetic and clinical •  Lots of data on acute coronary syndrome •  Dosing suggestion for severe RI in drug

monograph

Enoxaparin

•  Therapeutic –  ACS, severe RI (post-hoc analysis)

TE event 26% compared to no RI 17% (trend) Bleeding 6.6% compared to no RI 1.1% (sig.) Bleeding: No difference whether UFH-LMWH

–  Dosing scheme deduced and prospectively validated severe RI: use 65% of dose adjust to target peak anti-Xa 0.5 – 1.0 U/ml

Spinler et al. Am Heart J 2003:33-41 / Collet et al. Int J Cardiol 2001:81-2 & J Am Coll Cardiol 2003:8-14

Enoxaparin

•  Therapeutic –  ACCP & product monograph: dose reduction to 50%

•  Prophylactic –  ACCP & product monograph: dose reduction to 50% –  USA: 2x 30 mg/d à 1x 30 mg/d –  Europe: 1x 40 mg/d à 1x 20 mg/d

–  risk of under-dosage?

Hirsh. ACCP 8th Chest 2008:141S-59S / Swiss drug monograph / Montalescot. Circulation 2004:392-8

Nadroparin

•  Therapeutic – significant increase in peak anti-Xa already

with mild RI – calculated t½: 10 h with GFR 60 ml/min

Mismetti et al. Thromb Haemost 1998:1162-5

Dalteparin •  Prophylactic

–  ICU: n=138, CrCl 19 ± 7 ml/min anti-Xa in range 0.29 – 0.34 U/ml for median 7 days (IQR 4-12)

–  general ward: pharmacokinetics no bioaccumulation > 30% for median 10 days (4-13)

Douketis et al. Arch Intern Med 2008:1805-12 / Schmid et al. J Thromb Haemost 2009:552-8

Dalteparin •  Therapeutic

–  general ward: pharmacokinetics for median 6 days (IQR 4-10)

Schmid et al. J Thromb Haemost 2009:1629-32

Tinzaparin

•  Therapy without dose adjustment – 10 days in 8 patients

CrCl 20-29 ml/min no bioaccumulation

•  Prophylaxis – 8 days in 27 elderly patients

CrCl 37 ± 13 ml/min no significant bioaccumulation

Siguret et al. Thromb Haemost 2000:589-600 / Pautas et al. Drug Saf 2002:725-33

Tinzaparin •  IRIS: Therapy of VTE, RCT, 25% with CrCl ≤ 30 ml/min •  Evaluation on day 90 of treatment •  stopped after interim analysis

Leizorovicz et al. Thrombosis Research 2011:27-34

unadjusted Tinzaparin 175 U/kg/d

VKA (overlap)

UFH adjusted by aPTT

VKA (overlap)

RR (95% CI)

n 269 268

CrCl 39.9 ± 12.2 ml/min 39.8 ± 11.9 ml/min

Mean Exposure 7.9 d 7.5 d

Recurrent VTE 5.9% 3.4% 1.8 (0.8–3.9)

Bleeding (s.c. period) 6.7% 5.6% 1.2 (0.6–2.3)

Death any cause 11.5% 6.3% 1.8 (1.03-3.2)

Certoparin •  Prophylaxis •  sub-group analysis CERTIFY •  GFR ≤ 30 ml/min/1.73 m2

Bauersachs et al. Thromb Haemost 2011:981-8

Certoparin 3000 U/d UFH 5000 U 3x/d OR (95% CI)

n 97 92

Exposure 9.5 ± 3.9 d 9.1 ± 3.5 d

comb. TE events 6.5% 2.6% 2.60 (0.49 – 13.9)

Bleeding events 5% 14% 0.33 (0.11 – 0.97)

Death any cause 5.4% 5.8% 0.92 (0.26 – 3.30)

Summary I

•  Evaluate renal function, may change

•  VKA – adjust dose to INR target value – expect ~20% lower dose – avoid INR > 3

•  UFH – Adjust dose to monitoring

Summary II: LMWH & severe RI

•  Evaluate bleeding and thrombosis risk à UFH?

•  Monitor anti-Xa activity LMWH * Prophylaxis Therapy Certoparin 3000 U/d ? Dalteparin 5000 U/d ? adjust to anti-Xa Enoxaparin 50%: 20mg/d ? ~50%: detailed scheme Nadroparin ? ? Tinzaparin 4500 U/d ? 1x 175 U/ kg / d * alphabetically listed; summarizing table – evidence varies for each drug

“Old” anticoagulants

•  “well-known” anticoagulants – clinical experience –  rare side effects

•  Severe RI: evidence by clinical end-points still limited for several anticoagulants

pirmin.schmid@luks.ch

Acknowledgment Walter A. Wuillemin, MD PhD Andreas G. Fischer, MD Doreen Brodmann, MD